Good morning, myeloma world.

Have you ever gone for a walk on a hot summer day, with birds singing and insects buzzing and the sound of children and traffic in the distance, and all of a sudden you notice that all of the sounds that were there before aren't there any more, and it's really, really quiet? Like, scary quiet?

Well, that's how we feel right now here at Myeloma Morning Headquarters, be­cause we don't have a single new myeloma-related research study or business news item to report about.

Nada. Zilch. Zero. …

Good morning, myeloma world.

It's another rainy day here at Myeloma Morning Headquarters, and we're trying to stay positive by keeping in mind that old rhyme, “April showers bring May flowers.”

“Rain is good,” we keep telling ourselves. “Rain is good.”

But we're not so sure, so we're turning our attention to our main task today, which is getting you up to speed on what's new in myeloma world.

In that regard, we'll be focusing first on a brief study by myeloma special­ists at the Mayo Clinic. They've investigated the treatment and …

Good morning, myeloma world.

There are times when we write an edition of Myeloma Morning, and it turns out completely different than expected. Today's edition is a perfect example.

As we were planning today's report, we thought it would focus on two preclinical research studies examining the potential new myeloma therapies CCF642 and BDA-366.

And, yes, we do start today's report with summaries of those two studies.

But readers will be making a mistake if they stop after reading that section of today's article. Because the third study we …